| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRCLINONC.2017.30 |
| P698 | PubMed publication ID | 28290489 |
| P50 | author | Roberto Orecchia | Q105532303 |
| Jay Steven Loeffler | Q33124729 | ||
| Marco Durante | Q37834971 | ||
| P2860 | cites work | Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes | Q47793289 |
| To fractionate or not to fractionate? That is the question for the radiosurgery of hypoxic tumors | Q48443431 | ||
| Disregarding RBE variation in treatment plan comparison may lead to bias in favor of proton plans. | Q48566156 | ||
| Treatment of cancer with heavy charged particles. | Q48868356 | ||
| First experience of carbon-ion radiotherapy for early breast cancer. | Q50712151 | ||
| Rapid RBE-Weighted Proton Radiation Dosimetry Risk Assessment. | Q50866044 | ||
| In silico comparison of photons versus carbon ions in single fraction therapy of lung cancer. | Q51464877 | ||
| Impact of fractionation and number of fields on dose homogeneity for intra-fractionally moving lung tumors using scanned carbon ion treatment. | Q51570951 | ||
| Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. | Q51847962 | ||
| Inactivation of aerobic and hypoxic cells from three different cell lines by accelerated (3)He-, (12)C- and (20)Ne-ion beams. | Q52072889 | ||
| Heavy Ions in Cancer Therapy. | Q53045537 | ||
| Imaging Changes in Pediatric Intracranial Ependymoma Patients Treated With Proton Beam Radiation Therapy Compared to Intensity Modulated Radiation Therapy. | Q53377588 | ||
| Does Heavy Ion Therapy Work Through the Immune System? | Q53670611 | ||
| Beyond a moonshot: insurance coverage for proton therapy. | Q54651708 | ||
| Why Is Proton Beam Therapy So Controversial? | Q54772888 | ||
| Proton radiotherapy for primary liver cancers | Q57138905 | ||
| Radiation oncology health technology assessment—the best is the enemy of the good | Q57618234 | ||
| A 4D-optimization concept for scanned ion beam therapy | Q57780576 | ||
| Including oxygen enhancement ratio in ion beam treatment planning: model implementation and experimental verification | Q57780604 | ||
| Overcoming resistance of cancer stem cells | Q57780688 | ||
| A modified hypoxia-based TCP model to investigate the clinical outcome of stereotactic hypofractionated regimes for early stage non-small-cell lung cancer (NSCLC) | Q60393653 | ||
| Technology assessment in radiation oncology: time for reassessment? | Q81358771 | ||
| Point/counterpoint: we do not need randomized clinical trials to demonstrate the superiority of proton therapy | Q83826526 | ||
| Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck | Q86170360 | ||
| Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach | Q86939747 | ||
| New Ions for Therapy | Q91478409 | ||
| The Future of Combining Carbon-Ion Radiotherapy with Immunotherapy: Evidence and Progress in Mouse Models | Q91478509 | ||
| Protons, Photons, and the Prostate - Is There Emerging Evidence in the Ongoing Discussion on Particle Therapy for the Treatment of Prostate Cancer? | Q26767399 | ||
| Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis | Q26772137 | ||
| Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response | Q27009437 | ||
| Proton radiobiology | Q27025061 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Exploiting tumour hypoxia in cancer treatment | Q28264146 | ||
| Past, present, and future of radiotherapy for the benefit of patients | Q28280008 | ||
| Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer | Q28552089 | ||
| Imaging biomarker roadmap for cancer studies | Q30242020 | ||
| Recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: a model for Canada? | Q30428790 | ||
| Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data | Q30627447 | ||
| Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. | Q31144917 | ||
| Charged particles in radiation oncology | Q33273594 | ||
| Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study | Q33273950 | ||
| Impact of enhancements in the local effect model (LEM) on the predicted RBE-weighted target dose distribution in carbon ion therapy. | Q33274600 | ||
| Reoptimization of Intensity Modulated Proton Therapy Plans Based on Linear Energy Transfer | Q33276287 | ||
| New challenges in high-energy particle radiobiology | Q33782346 | ||
| Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer | Q34268907 | ||
| A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group | Q35138181 | ||
| Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two facto | Q35568485 | ||
| High-LET radiotherapy for adenoid cystic carcinoma of the head and neck: 15 years' experience with raster-scanned carbon ion therapy | Q35688893 | ||
| Radiation quality-dependence of bystander effect in unirradiated fibroblasts is associated with TGF-β1-Smad2 pathway and miR-21 in irradiated keratinocytes | Q35746494 | ||
| Modeling Combined Chemotherapy and Particle Therapy for Locally Advanced Pancreatic Cancer | Q35820403 | ||
| Kill-painting of hypoxic tumours in charged particle therapy. | Q36310285 | ||
| Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. | Q36507549 | ||
| Randomized controlled trials in health technology assessment: overkill or overdue? | Q36516936 | ||
| Imaging changes in very young children with brain tumors treated with proton therapy and chemotherapy | Q36612126 | ||
| Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial | Q36673860 | ||
| Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. | Q36688010 | ||
| New Clinical and Research Programs in Particle Beam Radiation Therapy: The University of California San Francisco Perspective | Q36806074 | ||
| International Symposium on Ion Therapy: Planning the First Hospital-Based Heavy Ion Therapy Center in the United States | Q36817751 | ||
| Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma | Q36914411 | ||
| Systemic effects of local radiotherapy | Q37539309 | ||
| Stereotactic body radiation therapy: a novel treatment modality | Q37649474 | ||
| Motion in radiotherapy: particle therapy | Q37903204 | ||
| Organ-sparing radiation therapy for head and neck cancer | Q37905536 | ||
| Real-time tumour tracking in particle therapy: technological developments and future perspectives. | Q38039264 | ||
| Imaging hypoxia to improve radiotherapy outcome | Q38059626 | ||
| Image-guided radiotherapy: from current concept to future perspectives | Q38060971 | ||
| Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? | Q38062793 | ||
| Clinical controversies: proton therapy for thoracic tumors | Q38087712 | ||
| Health economic controversy and cost-effectiveness of proton therapy | Q38087714 | ||
| Charged particle therapy--optimization, challenges and future directions | Q38108208 | ||
| Evolution of advanced technologies in prostate cancer radiotherapy | Q38135708 | ||
| Patterns of failure after proton therapy in medulloblastoma; linear energy transfer distributions and relative biological effectiveness associations for relapses. | Q38187509 | ||
| Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis | Q38224910 | ||
| Progress and controversies: Radiation therapy for prostate cancer | Q38252429 | ||
| Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer | Q38264160 | ||
| Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience | Q38339108 | ||
| Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future? | Q38367507 | ||
| Proton therapy for head and neck cancer | Q38391797 | ||
| Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. | Q38393038 | ||
| Advances in Radiotherapy for Head and Neck Cancer | Q38412635 | ||
| Intensity modulated proton therapy | Q38414155 | ||
| Linear energy transfer painting with proton therapy: a means of reducing radiation doses with equivalent clinical effectiveness. | Q38415515 | ||
| LET-painting increases tumour control probability in hypoxic tumours | Q38424605 | ||
| Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting | Q38455283 | ||
| X-rays vs. carbon-ion tumor therapy: cytogenetic damage in lymphocytes | Q38496690 | ||
| The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence | Q38536374 | ||
| Opportunities and challenges of radiotherapy for treating cancer | Q38539957 | ||
| Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions | Q38543109 | ||
| Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line? | Q38549486 | ||
| Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy for Clinically Localized Prostate Cancer: How Good Is the Evidence? | Q38637563 | ||
| Breast cancer therapy-associated cardiovascular disease | Q38645182 | ||
| Clinical Outcomes and Toxicity of Proton Radiotherapy for Breast Cancer. | Q38781776 | ||
| Radiation oncology in the era of precision medicine. | Q38786662 | ||
| Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer | Q38794011 | ||
| Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer | Q38809754 | ||
| Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects | Q38818713 | ||
| The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells | Q38819926 | ||
| Proton therapy for paediatric CNS tumours - improving treatment-related outcomes. | Q38838663 | ||
| FDG and Beyond | Q38869438 | ||
| Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer | Q38904093 | ||
| European cancer mortality predictions for the year 2016 with focus on leukaemias | Q38915866 | ||
| Nuclear physics in particle therapy: a review | Q38931739 | ||
| Radiotherapy and immunotherapy: a beneficial liaison? | Q39017268 | ||
| Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma | Q39173517 | ||
| First experimental-based characterization of oxygen ion beam depth dose distributions at the Heidelberg Ion-Beam Therapy Center | Q39584662 | ||
| Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617. | Q39748985 | ||
| Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation | Q39758735 | ||
| Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer | Q39846579 | ||
| Helium ions for radiotherapy? Physical and biological verifications of a novel treatment modality | Q39871083 | ||
| Can particle beam therapy be improved using helium ions? - a planning study focusing on pediatric patients. | Q40124111 | ||
| Results of heavy ion radiotherapy | Q40440436 | ||
| Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer | Q40789166 | ||
| Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study | Q40938733 | ||
| Long-term Results of the UCSF-LBNL Randomized Trial: Charged Particle With Helium Ion Versus Iodine-125 Plaque Therapy for Choroidal and Ciliary Body Melanoma | Q41116165 | ||
| Combined intensity-modulated radiotherapy plus raster-scanned carbon ion boost for advanced adenoid cystic carcinoma of the head and neck results in superior locoregional control and overall survival | Q41694230 | ||
| Range modulation in proton therapy planning: a simple method for mitigating effects of increased relative biological effectiveness at the end-of-range of clinical proton beams | Q41895634 | ||
| Multigating, a 4D optimized beam tracking in scanned ion beam therapy | Q42424205 | ||
| Risk of ischemic heart disease in women after radiotherapy for breast cancer | Q43615460 | ||
| A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis | Q43874046 | ||
| Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group | Q44070976 | ||
| Chromosome inversions in lymphocytes of prostate cancer patients treated with X-rays and carbon ions | Q45205408 | ||
| Fragmentation of 120 and 200 MeV u-14He ions in water and PMMA targets | Q46429048 | ||
| Establishing Cost-Effective Allocation of Proton Therapy for Breast Irradiation | Q47772485 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 483-495 | |
| P577 | publication date | 2017-03-14 | |
| P1433 | published in | Nature Reviews Clinical Oncology | Q641640 |
| P1476 | title | Charged-particle therapy in cancer: clinical uses and future perspectives | |
| P478 | volume | 14 |
| Q47220408 | 3D-structured illumination microscopy reveals clustered DNA double-strand break formation in widespread γH2AX foci after high LET heavy-ion particle radiation. |
| Q93053380 | Assessing the interactions between radiotherapy and antitumour immunity |
| Q55252795 | Assessing the uncertainty in a normal tissue complication probability difference (∆NTCP): radiation-induced liver disease (RILD) in liver tumour patients treated with proton vs X-ray therapy. |
| Q89967035 | Carbon Ion Therapy: A Modern Review of an Emerging Technology |
| Q92857877 | Carbon ion radiotherapy as a treatment modality for paediatric cancers |
| Q64261918 | Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche |
| Q55282213 | Case-report: Metastases in a low-stage middle-graded HCC in cleared HCV infection, non-cirrhotic liver: Surgical therapy. |
| Q64275109 | Challenges and Contradictions of Metal Nano-Particle Applications for Radio-Sensitivity Enhancement in Cancer Therapy |
| Q99545845 | Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma |
| Q57279966 | Clinical trials involving carbon-ion radiation therapy and the path forward |
| Q64388750 | Clustered DNA double-strand break formation and the repair pathway following heavy-ion irradiation |
| Q64249936 | Comparison of Proton and Photon Beam Irradiation in Radiation-Induced Intestinal Injury Using a Mouse Model |
| Q91741550 | Comparison of the effects of photon, proton and carbon-ion radiation on the ecto-calreticulin exposure in various tumor cell lines |
| Q64059996 | Comparison of transcriptional profiles in human lymphocyte cells irradiated with C ion beams at 0-2.0 Gy |
| Q48054504 | Differential gene expression in primary fibroblasts induced by proton and cobalt-60 beam irradiation. |
| Q51415582 | Do protons and X-rays induce cell-killing in human peripheral blood lymphocytes by different mechanisms? |
| Q89848036 | Dosimetric evaluation of MR-derived synthetic-CTs for MR-only proton treatment planning |
| Q47109232 | Editorial: Charged Particles in Oncology |
| Q48263273 | Effects of crystallographic and geometric orientation on ion beam sputtering of gold nanorods. |
| Q52671904 | Evolution of Carbon Ion Radiotherapy at the National Institute of Radiological Sciences in Japan. |
| Q90193333 | FGFR Signaling as a Candidate Therapeutic Target for Cancers Resistant to Carbon Ion Radiotherapy |
| Q64925881 | Gene Expression Studies for the Development of Particle Therapy. |
| Q103002286 | Inter-fractional monitoring of [Formula: see text]C ions treatments: results from a clinical trial at the CNAO facility |
| Q100697471 | Investigating the use of virtual 4DCT from 4DMRI in gated carbon ion radiation therapy of abdominal tumors |
| Q90028604 | Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices |
| Q95642957 | Medical Gas Plasma Jet Technology Targets Murine Melanoma in an Immunogenic Fashion |
| Q104568231 | Model-based comparison of organ at risk protection between VMAT and robustly optimised IMPT plans |
| Q89449749 | Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study "GUNMA0702" |
| Q57167684 | Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy |
| Q49592283 | New insights in the relative radiobiological effectiveness of proton irradiation. |
| Q58618176 | Opportunistic dose amplification for proton and carbon ion therapy via capture of internally generated thermal neutrons |
| Q47133392 | Particle therapy and nanomedicine: state of art and research perspectives. |
| Q58723292 | Phase I Study of Carbon Ion Radiotherapy and Image-Guided Brachytherapy for Locally Advanced Cervical Cancer |
| Q90106949 | Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study |
| Q90370759 | Proton beam therapy in Europe: more centres need more research |
| Q47438065 | Radiation therapy-induced metastasis: radiobiology and clinical implications. |
| Q49287618 | Radiation-Induced Cardiovascular Disease: Mechanisms and Importance of Linear Energy Transfer |
| Q55294642 | Radiation-Induced Chromosomal Aberrations and Immunotherapy: Micronuclei, Cytosolic DNA, and Interferon-Production Pathway. |
| Q64386954 | Radiation-induced DNA damage cooperates with heterozygosity of TP53 and PTEN to generate high grade gliomas |
| Q90049987 | Radiogenomic Predictors of Adverse Effects following Charged Particle Therapy |
| Q59800169 | Radiotherapy improves the survival of patients with extensive-disease small-cell lung cancer: a propensity score matched analysis of Surveillance, Epidemiology, and End Results database |
| Q58702829 | Radiotherapy improves the survival of patients with stage IV NSCLC: A propensity score matched analysis of the SEER database |
| Q89596081 | Recent advances in radiation oncology |
| Q60950143 | Recruitment of 53BP1 Proteins for DNA Repair and Persistence of Repair Clusters Differ for Cell Types as Detected by Single Molecule Localization Microscopy |
| Q89956053 | Small-molecule drug repurposing to target DNA damage repair and response pathways |
| Q96576503 | Specificity of end resection pathways for double-strand break regions containing ribonucleotides and base lesions |
| Q92358102 | Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy |
| Q89988131 | Technology-driven research for radiotherapy innovation |
| Q47577540 | The 150 most important questions in cancer research and clinical oncology series: questions 67-75 : Edited by Chinese Journal of Cancer |
| Q92941721 | The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response |
| Q57149480 | The Relative Biological Effect of Spread-Out Bragg Peak Protons in Sensitive and Resistant Tumor Cells |
| Q97586865 | The societal impact of ion beam therapy |
| Q90407178 | Three discipline collaborative radiation therapy (3DCRT) special debate: The United States needs at least one carbon ion facility |
| Q56804507 | Three ways to make proton therapy affordable |
| Q90199238 | Validation of the RayStation Monte Carlo dose calculation algorithm using realistic animal tissue phantoms |
Search more.